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Getting to Know Your Board Members – 
Patrick Gannon
This quarter, the Massachusetts Board of  Registration in 
Pharmacy is shining a spotlight on one of  its longest tenured 
Board members, Patrick Gannon, RPh, who was appointed 
to the Board in December 2012.
Patrick’s first connection with pharmacy started in high 
school when he worked as a front shop clerk in a privately-
owned retail pharmacy. This experience sparked his interest 
in a pharmacy career. A year prior to graduation from phar-
macy school, he began to work at a local hospital pharmacy, 
and from there his career path advanced rather quickly to 
staff pharmacist, supervisor, and director. Simultaneously, 
his role at the hospital expanded into quality improvement 
work; an administrative position over several departments; 
and most recently, as chief quality officer. Patrick’s current 
role allows him to interact with pharmacy service leaders 
within a health system.
Throughout his career, Patrick has had an affinity for 
statutory and regulatory topics, with a personal goal to add 
greater clarity to regulatory language. Becoming a Board 
member was the opportunity he needed to help revise regu-
lations, so they may be clear and useful tools for licensees.
Prior to his appointment, Patrick had little knowledge of 
the extent of the Board’s operations and the role of  Board 
members, but he adjusted quickly. “In my experience, the 
Board staff addresses a very wide array of responsibilities 
in a very efficient, collegial, and supportive manner,” says 
Patrick. “Appointed Board members hold a significant re-
sponsibility and opportunity to work very collaboratively 
with Board staff and licensees alike. I am grateful for the 
opportunity to serve, as the position affords an additional 
venue to affect pharmacy practice in ways that can raise 
the bar for public safety at a regional level, combined with 
an ability to protect, preserve, and advance professional 
practice through Board activities.”
Patrick finished by saying, “Be thankful and supportive 
of your local Board; they work hard and act as advocates 
for doing the right thing in the name of  public safety.”
Update on Draft Regulations of 247 CMR 
6.00: Licensure of Pharmacies
The Board’s draft regulations of  247 Code of  Massachu-
setts Regulations (CMR) 6.00: Licensure of  Pharmacies are 
currently under administrative review for finalization. The 
current 247 CMR 6.00 has been revised to incorporate sev-
eral new licensing categories as mandated by the pharmacy 
reform legislation (An Act Relative to Pharmacy Practice in 
the Commonwealth). Some standards in the existing version 
of  247 CMR 6.00, such as requirements for a pharmacy and 
operation of a pharmacy will be relocated to the Board’s 
proposed regulations of  247 CMR 9.00: Professional Prac-
tice Standards. 
In addition to new licensing categories for sterile com-
pounding pharmacies (including institutional sterile com-
pounding pharmacies), the draft regulations include new 
licensing categories for complex nonsterile compounding 
pharmacies as well as nonresident pharmacies. 
At the December 2018 Board meeting, Board members 
voted to approve a final draft of the sterile compounding 
regulations (247 CMR 17.00: Sterile Compounding) and 
to move it on to the administrative review process. Based 
on the timeline of  proposed regulations, it is likely that the 
Board’s draft licensing regulations (247 CMR 6.00) will be 
promulgated prior to the new sterile compounding regula-
tions (247 CMR 17.00). 
This means that sterile compounding pharmacies licensed 
by the Board will be inspected on the current version of 
United States Pharmacopeia (USP) <797> until the new ster-
ile compounding regulations are promulgated. In addition 
to those USP <797> requirements, the Board’s inspection 
tool includes best practices based on the draft regulations 
and may go beyond USP <797> requirements. All of the 
Board’s draft regulations and current inspection tools can 
be found on the Board’s website.
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These initiatives include communicating to the public as 
soon as possible when there is a concern about a dietary 
supplement on the market, ensuring that the regulatory 
framework is flexible enough to adequately evaluate prod-
uct safety, and continuing to work closely with industry 
partners. FDA is also developing new enforcement strate-
gies to respond to entities that violate standards established 
under the Dietary Supplement Health and Education Act 
of 1994.   
On February 11, 2019, FDA sent 12 warning letters 
and five online advisory letters to foreign and domestic 
companies that are illegally selling more than 58 products. 
The products are illegally marketed as unapproved new 
drugs that make unproven claims about preventing, treat-
ing, or curing Alzheimer’s disease, as well as a number 
of other serious diseases and health conditions, such as 
diabetes and cancer. In his statement, Gottlieb noted that 
most stakeholders in the industry act responsibly, but he 
expressed concern over the ability of  bad actors to exploit 
the system by providing potentially dangerous products 
and making unproven or misleading claims about the 
health benefits supplements may offer.
 FDA is planning a public meeting on this topic during 
the second quarter of 2019. For more information, view 
the FDA statement at https://www.fda.gov/newsevents/
newsroom/pressannouncements/ucm631065.htm.  
Trump Administration Releases National 
Drug Control Strategy to Reduce Drug 
Trafficking and Abuse
As the opioid crisis continues to claim the lives of 
tens of thousands of Americans each year, the Office of 
National Drug Control Policy has released its National 
Drug Control Strategy. The Strategy breaks down the 
administration’s priorities in addressing the crisis, with 
an emphasis on three areas: prevention, treatment and 
recovery, and reducing availability.
♦ Prevention efforts are focused on educating both
consumers and caregivers about the dangers of opioid
misuse and include a new national media campaign,
continued efforts to expand prescription monitoring
programs (PMPs), and improving the ability of state,
local, and tribal communities to identify and prevent
substance abuse.
♦ Treatment and recovery recommendations in
the Strategy include improving access to naloxone,
improving evidence-based addiction treatment, and
eliminating barriers for accessing treatment.
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FDA Launches Pilot Program to Improve 
Security of Drug Supply Chain With an 
Innovative Approach
 Food and Drug Administration (FDA) has launched 
a pilot program allowing participants representing the 
various parts of the drug supply chain to pilot innova-
tive and emerging approaches for enhanced tracing and 
verification of prescription drugs in the United States’ 
supply chain. The program is in line with FDA’s ongoing 
efforts to prevent suspect and illegitimate products from 
entering the supply chain, according to an FDA press 
release. Eligible manufacturers, repackagers, and other 
stakeholders can apply to participate in the program, which 
will inform the development of the enhanced electronic, 
interoperable track-and-trace system for industry set to go 
into effect in 2023 in accordance with the Drug Supply 
Chain Security Act (DSCSA), enacted by Congress on 
November 27, 2013.
The pilot technologies of  this program may become part 
of FDA’s enhanced expectations for reliable track-and-
trace systems, which will be designed to reduce diversion 
of drugs distributed domestically and to keep counterfeit 
drugs from entering the supply chain. The DSCSA pilot 
project program is intended to help identify and evaluate 
the most efficient processes to comply with and apply 
drug supply chain security requirements and will aid in 
identifying attributes the system will need for enhanced 
product tracing and verification, as well as electronic 
means to share the information. FDA recently issued 
draft guidance on the use of product identifiers with a 
unique serial number to improve verification down to the 
package level. FDA has also provided draft guidance for 
verification systems to quarantine and investigate suspect 
and illegitimate drugs. 
Additional information on the FDA pilot program is 
available in a February 8, 2019 announcement in the 
Federal Register.
FDA Announces New Efforts to Increase 
Oversight and Strengthen Regulation of 
Dietary Supplements
Noting that three in four Americans now take at least one 
dietary supplement on a regular basis, and that the dietary 
supplement industry has expanded to include as many as 
80,000 different products for consumers, FDA Commis-
sioner Scott Gottlieb, MD, has announced new plans to 
increase the agency’s oversight of dietary supplements. 
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♦ Reducing availability strategies are focused on dis-
rupting illegal supply chains, defeating drug traffick-
ers, increased cooperation with international partners,
and combating illegal internet drug sales.
The document notes that the “most important criterion 
of  success” is saving lives and calls for the federal govern-
ment to work closely with state and local governments, as 
well as other stakeholders. Additional information, includ-
ing the full strategy document, is available on the White 
House website at https://www.whitehouse.gov/opioids. 
National Association of  Boards of  Pharmacy® (NABP®) 
and its member boards of pharmacy remain committed 
to advancing best practices for PMPs in the interest of 
public health. NABP’s PMP data sharing system, NABP 
PMP InterConnect®, facilitates the secure transfer of 
PMP data across state lines and provides an effective 
means of combating drug diversion and drug abuse 
nationwide. In addition, NABP and its member boards 
continue efforts to educate consumers about prescription 
drug safety. The NABP AWARXE® Prescription Drug 
Safety Program’s Drug Disposal Locator Tool has more 
than 6,000 disposal locations and continues to add new 
locations to provide consumers with a safe way to dis-
pose of medication and help prevent misuse and abuse 
of prescription medications. For more information about 
PMP InterConnect and the AWARXE program, visit the 
Initiatives section of the NABP website at www.nabp 
.pharmacy.
New Study Predicts Opioid Epidemic Will 
Worsen Over the Next Decade
More than 700,000 people will die from opioid over-
doses between 2016 and 2025, and annual overdose deaths 
will reach nearly 82,000 by 2025, estimates a new study 
published to JAMA Network Open. The estimate is based 
on an analysis of data from the National Survey on Drug 
Use and Health and the Centers for Disease Control and 
Prevention from 2002 to 2015.
Researchers also projected that intervention efforts 
focused on lowering the incidence of prescription opioid 
misuse would help to reduce the number of deaths 3.8% 
to 5.3%, a figure the researchers described as “modest,” 
due to the changing nature of the opioid crisis. The study 
notes that more people are directly initiating opioid use 
with illicit opioids rather than prescription drugs, and illicit 
opioids have become more lethal with the availability of 
illegally manufactured fentanyl.
The researchers encourage policymakers to take “a 
stronger and multipronged approach” to reduce the im-
pact of the ongoing opioid overdose epidemic. The full 
article is available at https://jamanetwork.com/journals/
jamanetworkopen/fullarticle/2723405.
FDA Warns of Potential Blood Pressure 
Medication Shortages Due to Recalls
 FDA is warning health care providers and consumers of 
a shortage of angiotensin II receptor blockers, commonly 
used to treat high blood pressure. A growing list of  medi-
cations containing valsartan, losartan, and irbesartan have 
been recalled from the market for containing an impurity 
that may present a cancer risk to patients. The issue was 
first detected in the summer of  2018, according to a state-
ment posted to the FDA website. Since then, FDA has 
placed a Chinese manufacturer of the active ingredient 
on import alert to stop their imports, and FDA is working 
with other manufacturers to recall affected medications.
 In the statement, FDA notes that the risk to individual 
patients remains very small, but that there is still reason 
to be concerned about the potential health risks. Medica-
tions with these impurities are believed to have been in 
the market for about four years.
 “Now that these risks are identified, we’re applying 
what we’ve learned to the evaluation of similar manufac-
turing processes where we now know these risks could 
arise,” the statement notes. The FDA press release is 
available at https://www.fda.gov/newsevents/newsroom/
pressannouncements/ucm629796.htm. 
FDA Releases Two Draft Guidances 
Related to REMS Programs
FDA has released two new draft guidances to ensure 
risk mitigation programs put in place for certain drugs 
and biologics, as required for approval, are working. The 
agency’s primary risk management tool is FDA-approved 
product labeling. However, in limited cases, FDA may 
require a Risk Evaluation and Mitigation Strategy (REMS) 
to help ensure a drug’s benefits outweigh its risks.
The following guidances relate to the assessment of 
REMS programs:
♦ REMS Assessment: Planning and Reporting
Guidance for Industry describes how to develop a
REMS Assessment Plan.
♦ Survey Methodologies to Assess REMS Goals
That Relate to Knowledge Guidance for Industry
provides recommendations on conducting REMS as-
sessment surveys to evaluate patient or health care
provider knowledge of REMS-related information.
FDA states that the goal in providing this guidance for 
REMS is to ensure constant improvement of their safety 
programs and establish the most efficient and effective 
programs moving forward, to optimize patient care and 
keep consumers safe and healthy. More information on 
REMS is available on the FDA website at https://www 
.fda.gov/drugs/drugsafety/rems.
National Pharmacy Compliance News May 2019
Page 4 – May 2019
The Massachusetts Board of Registration in Pharmacy News is published by the 
Massachusetts Board of Registration in Pharmacy and the National Association 
of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of phar-
macy and drug law. The opinions and views expressed in this publication do not 
necessarily reflect the official views, opinions, or policies of NABPF or the Board 
unless expressly so stated.
David Sencabaugh, RPh - Executive Director
Carmen A. Catizone, MS, RPh, DPh - National News Editor  
& Executive Editor
Amy Suhajda - Communications Manager
Technicians in Training 
Recently revised regulations of 247 CMR 8.03 now re-
quire all pharmacy technician trainees (PTTs) to be licensed 
by the Board. No individual may work as a technician 
trainee without holding a valid PTT license. The Board’s 
existing regulations impose certain qualifications for PTTs 
and limit the number of hours that an individual may be 
employed as a PTT. The license also provides prospective 
employers the ability to see if a trainee applicant has ever 
been involved in diversion or other misconduct.
An individual may not work as a PTT for more than 
1,500 hours or for more than one year, whichever period is 
shorter, unless the Board grants an extension. 
Board staff is authorized to grant an extension:
 ♦ for up to 90 days after the license expiration date
 ♦ if the individual has not yet reached 18 years of age 
(the license may be extended until the individual turns 
18 years old or for up to a year, whichever is sooner)
 ♦ if the individual has not yet completed at least 500 
hours of employment as a PTT (Board staff may ap-
prove a one-year extension)
CDTM Experience Equivalency
According to 247 CMR 16.02 and Massachusetts Gen-
eral Law Chapter 112 §24B1/2, a pharmacist must have 
five years of experience as a licensed pharmacist before 
participating in a collaborative drug therapy management 
(CDTM) agreement. However, the Board has recently 
released an advisory regarding education that would be 
considered equivalent to five years of experience. 
Pharmacists without five years of experience who wish 
to participate in a CDTM agreement must meet one of  the 
following conditions:
1. certification from the Board of  Pharmacy Specialties
2. completion of  a postgraduate year one residency that 
is American Society of Health-System Pharmacists 
(ASHP)-accredited and one of the following:
a. two additional years of experience as a 
pharmacist or 
b. twelve months of CDTM practice under a CDTM-
practicing pharmacist
3. completion of  a postgraduate year two residency that 
is ASHP-accredited and one of the following: 
a. one additional year of experience as a pharmacist 
or 
b. six months of CDTM practice under a CDTM-
practicing pharmacist
If a pharmacist does not meet these requirements, but 
would still like to be considered for a CDTM agreement, 
he or she can petition the Board for consideration of other 
education, residency, or experience.
Substance Use Disorder and Mental 
Health Medication Administration
Under 105 CMR 700.004(B)(9) and Circular: Drug Con-
trol Program 19-2-105, pharmacists and pharmacy interns 
are permitted to administer certain medications for mental 
illness and substance use disorder. Guidance on how to pro-
ceed has been given for both prescribers and pharmacists/
pharmacy interns who wish to provide this optional service.
The circular letter furnishes requirements such as train-
ing, CPR, and counseling. The circular letter also includes 
a list of approved medications that may be administered to 
patients 18 years of age or older. 
For clarity, the best practice is for the prescriber to write 
“for pharmacist administration” on the prescription. If  there 
is any question regarding the intent for pharmacist or other 
provider administration, you are encouraged to contact the 
provider.
Did You Know?
Patients or their agents do not need an ID to pick up 
prescriptions for federally controlled substances in certain 
circumstances. However, the person must print his or her 
name and address on the reverse side of  the prescription and 
sign his or her name. In the case of  an electronic prescrip-
tion, he or she must provide an electronic signature. Review 
the Data Submission Dispenser Guide for details.
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